Safety and Tolerability of Tegaserod for Irritable Bowel Syndrome
نویسنده
چکیده
INTRODUCTION Tegaserod maleate (ZelnormTM, Novartis) is a unique pharmacological agent for the treatment of patients with irritable bowel syndrome (IBS) with constipation (IBS-C). Unlike traditional IBS therapies, which target only single IBS symptoms, tegaserod has provided global relief of the multiple symptoms of IBS, including abdominal pain and discomfort, bloating, and constipation.1–4 It has also been found to be safe and well tolerated in both short-term (three-month) and longterm (12-month) clinical trials.5–7
منابع مشابه
Systematic review: the safety and tolerability of pharmacological agents for treatment of irritable bowel syndrome--a European perspective.
AIM To use an evidence-based approach to evaluate the safety and tolerability of the treatments available for irritable bowel syndrome (IBS), or in clinical development, in Europe. A separate review appraises the evidence for the efficacy of these therapies. METHODS A literature search (for 1980 to 2005) was completed for all relevant clinical trial data and other articles which included safe...
متن کاملReview article: tegaserod -- the global experience.
Studies from the Western hemisphere have established the efficacy and safety of tegaserod in women with irritable bowel syndrome and constipation. This review summarizes the results of recent studies from around the world that confirm the efficacy and safety of tegaserod, and expand our understanding of the role of this drug in the treatment of patients with irritable bowel syndrome.
متن کاملA randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation.
BACKGROUND It has been proposed that treatments for irritable bowel syndrome with constipation (IBS-C) should provide rapid symptomatic relief, be intermittent, and effective upon repeated use. AIMS To evaluate the efficacy and safety of tegaserod on IBS symptoms, and its impact on quality of life and health economic measures. PATIENTS Women (> or = 18 years of age) with IBS-C according to ...
متن کاملSafety and efficacy of tegaserod therapy in patients with irritable bowel syndrome or chronic constipation.
BACKGROUND Tegaserod, a 5-HT4 agonist, is effective for treating irritable bowel syndrome and chronic constipation. However, sales of this drug were recently suspended due to concerns about a higher rate of cardiovascular events in patients receiving tegaserod over placebo in clinical trials. Our aim was to review patients in our practice prescribed tegaserod to determine if any of them had suf...
متن کاملNEUROGASTROENTEROLOGY A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation
Background: It has been proposed that treatments for irritable bowel syndrome with constipation (IBS-C) should provide rapid symptomatic relief, be intermittent, and effective upon repeated use. Aims: To evaluate the efficacy and safety of tegaserod on IBS symptoms, and its impact on quality of life and health economic measures. Patients: Women (>18 years of age) with IBS-C according to the Rom...
متن کامل